Bloom Burton Issues Optimistic Forecast for TSE:MDP Earnings

Medexus Pharmaceuticals Inc. (TSE:MDP) – Stock analysts at Bloom Burton boosted their Q3 2025 earnings per share estimates for Medexus Pharmaceuticals in a research report issued to clients and investors on Thursday, January 23rd. Bloom Burton analyst D. Martin now anticipates that the company will earn $0.10 per share for the quarter, up from their previous estimate of $0.04. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Bloom Burton also issued estimates for Medexus Pharmaceuticals’ FY2025 earnings at $0.17 EPS, FY2026 earnings at ($0.24) EPS and FY2027 earnings at $0.69 EPS.

A number of other equities research analysts also recently issued reports on the stock. Alliance Global Partners raised shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, December 23rd. Raymond James raised Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price target for the company in a research report on Wednesday, January 8th. Stifel Nicolaus raised their target price on Medexus Pharmaceuticals from C$4.15 to C$4.50 in a research report on Tuesday, January 14th. Ventum Cap Mkts raised shares of Medexus Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 17th. Finally, Leede Financial raised shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, January 22nd. One investment analyst has rated the stock with a buy rating and five have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Medexus Pharmaceuticals presently has an average rating of “Strong Buy” and an average target price of C$5.58.

Medexus Pharmaceuticals Price Performance

MDP opened at C$4.60 on Monday. The firm’s fifty day moving average price is C$3.30 and its two-hundred day moving average price is C$2.74. The company has a market capitalization of C$112.84 million, a price-to-earnings ratio of 92.00 and a beta of 1.96. Medexus Pharmaceuticals has a 1 year low of C$1.47 and a 1 year high of C$5.56.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.